1. Bahn R.S., Burch H.B., Cooper D.S., Garber J.R. McDougall I.R., Montori V.M.,, Greenlee M.C., Klein I., Laurberg P., Rivkees S.A., Ross D.S., Sosa J.A., Stan M.N. ATA Guidelines: Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American As- sociation of Clinical Endocrinologists. Thyroid 2011, V. 21, N 6, 593-630.
2. Smith BR, Sanders J, Furmaniak J. TSH receptor antibodies. Thyroid. 2007 Oct;17(10):923-38.
3. Brown RS. Autoimmune thyroid disease: unlocking a complex puzzle. Curr Opin Pediatr. 2009 Aug;21(4):523-8
4. Segni M, Leonardi E, Mazzoncini B, Pucarelli I, Pasquino AM. Special features of Graves’ disease in early childhood. Thyroid. 1999 Sep;9(9):871-7.
5. Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW. Auto- immune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemi-cal features at diagnosis and responses to medical therapy. Thyroid. 1997 Oct;7(5):755-60.
6. Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves’ disease is ra- dioiodine. J Clin Endocrinol Metab. 2007 Mar; 92(3):797-800.
7. Zophel K, Roggenbuck D, Wunderlich G, Schott M. Continuously increasing sensitivity over three generations of TSH receptor autoantibody assays. Horm Metab Res. 2010 Nov;42(12):900-2.
8. Ajjan RA, Weetman AP. Techniques to quantify TSH receptor antibodies. Nat Clin Pract Endocrinol Metab. 2008 Aug;4(8):461-8.
9. Smith J, Brown RS. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves’ disease treated using antithyroid medication. Thyroid. 2007 Nov;17(11):1103-7.
10. Pedersen IB, Handberg A, Knudsen N, Heickendorff L, Laurberg P. Assays for thyroid-stimulating hormone receptor antibodies employing different ligands and ligand partners may have similar sensitivity and specificity but are not inter- changeable. Thyroid. 2010 Feb;20(2):127-33.
11. Hermsen D, Eckstein A, Schinner S, Willenberg HS, Thiel A, Scherbaum WA, et al. Reproducibility of Elecsys anti-TSHR test results in a lot-to-lot comparison. Horm Metab Res. 2010 Apr;42(4):295-7
12. Lytton SD, Kahaly GJ. Bioassays for TSH-receptor autoantibodies: an update. Autoimmun Rev. 2010 Dec;10(2):116-22.
13. Glaser NS, Styne DM. Predicting the likelihood of remission in children with Graves’ disease: a prospective, multicenter study. Pediatrics, 2008, Mar;121(3): e 481-8.
14. Rahhal SN, Eugster EA. Thyroid stimulating immunoglobulin is often negative in children with Graves’ disease. J Pediatr Endocrinol Metab. 2008 Nov; 21 (11): 1085-8.
15. Rivkees SA, Stephenson K, Dinauer C. Adverse events associated with methi- mazole therapy of graves’ disease in children. Int J Pediatr Endocrinol. 2010:176970.
16. Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endo- crinol Metab. 2009 Jun; 94(6):1881-2.
17. Brown RS. Disorders of the Thyroid Gland in Infants, Children, and Adoles- cents. In DeGroot L.J., Thyroid Disease Manager, http://www.thyroidmanager.org, published by Endocrine Education, Inc, South Dartmouth, MA, USA.
18. Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methi-mazole in children. J Clin Endocrinol Metab. 2010 Jul;95(7):3260-7.
19. Kaguelidou F, Carel JC, Leger J. Graves disease in childhood: advances in management with antithyroid drug therapy. Horm Res 2009;71: 310-317.
20. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab. 1987 Jun;64(6):1241-5.
21. Bergman P, Auldist AW, Cameron F. Review of the outcome of management of Graves’ disease in children and adolescents. J Paediatr Child Health. 2001 Apr;37(2):176-82.
22. Raza J, Hindmarsh PC, Brook CG. Thyrotoxicosis in children: thirty years’ ex- perience. Acta Paediatr. 1999 Sep; 88(9):937-41.
23. Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab. 1985 May; 60(5):1019-24.
24. Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab. 2008 Oct;93(10):3817-26.
25. Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, et al. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves’ disease: a 120 months prospec-tive study. Endocr J. 2007 Dec;54(5):713-20.
26. Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics. 2003 Apr; 111(4 Pt 1):745-9.
27. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Ra- diat Res. 1995 Mar;141(3):259-77.
28. Rivkees SA, Sklar C, Freemark M. Clinical review 99: The management of Graves’ disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab. 1998 Nov; 83(11):3767-76.
29. Sherman J, Thompson GB, Lteif A, Schwenk WF, 2nd, van Heerden J, Farley DR, et al. Surgical management of Graves disease in childhood and adolescence: an institutional expe-rience. Surgery. 2006 Dec; 140(6):1056-61; discussion 61-2.